Assessing the Antifungal Activity of a New Oral Lipid-Based Amphotericin B Formulation Following Administration to Rats Infected with Aspergillus Fumigatus

Author： Risovic Verica   Rosland Mike   Sivak Olena   Wasan Kishor M.   Bartlett Karen  

Publisher： Informa Healthcare

ISSN： 0363-9045

Source： Drug Development and Industrial Pharmacy, Vol.33, Iss.7, 2007-07, pp. : 703-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats

By Ibrahim Fady   Gershkovich Pavel   Sivak Olena   Wasan Ellen K.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 39, Iss. 9, 2013-09 ,pp. : 1277-1283

Informa Healthcare

Access to resources Recommend Favorite

Heat-Treated Fungizone Retains Amphotericin B Antifungal Activity Without Renal Toxicity in Rats Infected with Aspergillus Fumigatus

By Sivak Olena   Bartlett Karen   Wasan Kishor M.  

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1564-1566

Springer Publishing Company

Access to resources Recommend Favorite

Differences in human phospholipid transfer protein activity following incubation of Fungizone® compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma

By Henderson Ryan J.   Leon Carlos G.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 35, Iss. 9, 2009-09 ,pp. : 1139-1146

Informa Healthcare

Access to resources Recommend Favorite

Guidelines for lipid-based amphotericin B in SCT

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 306, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Guidelines for lipid-based amphotericin B in SCT

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite